US FDA approves Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-approved test.

https://www.roche.com/media/releases/med-cor-2021-10-15b.htm

Source: Roche Media News - October 15, 2021 Category: Pharmaceuticals Source Type: news